Press Releases

Release year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Release Tag:

December 17, 2014
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment

December 02, 2014
3-V Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference

November 12, 2014
Neuren's NNZ-2566 Successful in Demonstrating Clinical Benefit in Rett Syndrome Phase 2 Trial

November 10, 2014
Alchemia Announces Departure of Chief Executive Officer

October 26, 2014
Alchemia Announces Phase III Trial Results for HA-Irinotecan in Metastatic Colorectal Cancer

October 09, 2014
Alchemia Announces Database Lock of Its HA-Irinotecan Pivotal Phase III Trial in Metastatic Colorectal Cancer

October 06, 2014
Genetic Technologies Announces Quarterly BREVAGen(TM) Results

October 01, 2014
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test

September 24, 2014
Genetic Technologies Announces Appointment of Independent Non-Executive Directors

September 22, 2014
Genetic Technologies Announces Divestment of Australian Based Heritage Business

September 15, 2014
Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of Financing

August 26, 2014
Genetic Technologies Announces Further Patent Success in USA

August 25, 2014
Alchemia Appoints Jenni Pilcher as Chief Financial Officer

July 30, 2014
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec

July 07, 2014
Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014

June 30, 2014
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer

June 20, 2014
Alchemia Announces First Patient Enrolled in Investigator-Led Phase II Trial of HA-Irinotecan and Erbitux ("CHIME" Trial)

June 05, 2014
Alchemia Updates Timeline for Completion of Pivotal Phase III Trial of HA-Irinotecan in Metastatic Colorectal Cancer

May 28, 2014
Genetic Technologies Announces Appointment of Chief Financial Officer

May 16, 2014
Genetic Technologies Announces Completion of Share Transaction With Dr. Mervyn Jacobson

April 30, 2014
Genetic Technologies Files Activities Report for the Quarter Ended March 31, 2014

April 17, 2014
Results From Extraordinary General Meeting

April 07, 2014
Alchemia Announces Presentation of Data on Its Discovery of a Potential New Cancer Stem Cell Therapeutic Target During the 2014 AACR Annual Meeting

March 24, 2014
Genetic Technologies Executes Agreement With Promega Corporation

March 07, 2014
Genetic Technologies Announces Publication of Economic Modeling Study Supporting Cost-Effectiveness of BREVAGen(TM) to Direct Tamoxifen Chemoprevention

March 03, 2014
Alchemia to Present at the 26th Annual ROTH Conference on March 12, 2014

February 27, 2014
Alchemia to Present at the Cowen and Company 34th Annual Health Care Conference on March 3, 2014

February 24, 2014
Genetic Technologies Provides Further Update on Corporate Structure

February 24, 2014
Alchemia Appoints Thomas Liquard as Chief Executive Officer

February 19, 2014
Alchemia Announces Quarterly Fondaparinux Profit Share

February 18, 2014
Alchemia Announces Half-Year Results for Period Ended 31 December 2013

February 18, 2014
Nexvet Biopharma to Present at the Cowen and Company 34th Annual Health Care Conference on March 5, 2014

February 12, 2014
Genetic Technologies Announces Update on Intellectual Property

February 11, 2014
Alchemia Announces Appointment of Santo J. Costa as Chairman

January 30, 2014
Genetic Technologies Provides Corporate and Financial Update for Quarter Ended December 31, 2013

January 08, 2014
Genetic Technologies Announces New Record Growth in Number of BREVAGen(TM) Tests Received for December Quarter